TORRENT PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 2.0%

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 2.0%
Tue, 28 Jan

TORRENT PHARMA has announced its results for the quarter ended December 2019. Here is a detailed performance review of the same:

TORRENT PHARMA Quarterly Financials

No. of Mths
Qtr. Ending
3
Dec-18*
3
Sep-19*
3
Dec-19*
QoQ ChangeYoY Change
Net SalesRs m20,51020,05019,660-1.9%-4.1%
Other incomeRs m3034053055.9%1666.7%
TurnoverRs m20,54020,39020,190-1.0%-1.7%
ExpensesRs m14,90014,64014,260-2.6%-4.3%
Gross profitRs m5,6105,4105,400-0.2%-3.7%
DepreciationRs m1,5601,6301,6300.0%4.5%
InterestRs m1,3301,1601,110-4.3%-16.5%
Profit before taxRs m2,7502,9603,1907.8%16.0%
TaxRs m29052068030.8%134.5%
Profit after taxRs m2,4602,4402,5102.9%2.0%
Gross profit margin%27.427.027.5
Effective tax rate%10.517.621.3
Net profit margin%12.012.012.4
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster


Year-on-Year Performance:
  • The company's operating income during the quarter fell 4.1% on a year-on-year (YoY) basis. The expenses were down by 4.3% YoY during the same period.
  • The company's operating profit declined by 3.7% YoY during the quarter. Consequently, operating profit margins remained same and stood at 27.5% in 3QFY20.
  • Depreciation charges increased by 4.5% and finance costs declined by 16.5% YoY, respectively.
  • Other income increased by 1666.7% YoY during the quarter.
  • Net profit for the quarter increased by 2.0% YoY. Net profit margins during the quarter increased from 12.0% in 3QFY19 to 12.4% in 3QFY20.
Quarter-on-Quarter Performance:
  • The company's operating income during the quarter fell 1.9% on a quarter-on-quarter (QoQ) basis. The expenses were down by 2.6% QoQ during the same period.
  • The company's operating profit declined by 0.2% QoQ during the quarter. Consequently, operating profit margins witnessed a growth and stood at 27.5% in 3QFY20 as against 27.0% in 2QFY19.
  • Net profit for the quarter increased by 2.9% QoQ, while net profit margins increased from 12.0% in 2QFY19 to 12.4% in 3QFY20.

To see how TORRENT PHARMA has performed over the last eight quarters,please visit here.

Watch Full Replay: Rahul Shah's Lazy Millionaire Summit

TORRENT PHARMA Share Price Performance

Over the last one year,TORRENT PHARMA share price has moved up from Rs 1,848.2 to Rs 1,915.9, registering a Gain of Rs 67.7 or around 3.7%.

Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 14,334.9 (up 0.2%). Over the last one year it has moved up from 13,658.2 to 14,334.9, a gain of 677 points (up 5.0%).

Overall, the S&P BSE SENSEX is up 15.2% over the year.

Current Valuations

At the current price of Rs 1,915.9, the price to earnings (P/E) ratio of TORRENT PHARMA stands at 58.0 times its trailing twelve months earnings, while its price to book value (P/BV) ratio stands at 6.9 times.

Equitymaster requests your view! Post a comment on "TORRENT PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 2.0%". Click here!

  

Related Views on News

TORRENT PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 27.0% (Quarterly Result Update)

Oct 27, 2020 | Updated on Oct 27, 2020

For the quarter ended September 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 27.0% YoY). Sales on the other hand came in at Rs 20 bn (up 0.6% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 48.6% (Quarterly Result Update)

Jul 31, 2020 | Updated on Jul 31, 2020

For the quarter ended June 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 48.6% YoY). Sales on the other hand came in at Rs 21 bn (up 1.7% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

More Views on News

Most Popular

Tata Steel vs SAIL: Which Stock is Better?(Views On News)

Jan 13, 2022

With government initiatives set to boost the steel sector, find out who has a better chance of coming out on top.

These 5 Penny Stocks are Held by Rakesh Jhunjhunwala. Worth a Look?(Views On News)

Jan 18, 2022

Rakesh Jhunjhunwala is holding these penny stocks in his portfolio for several years now.

Watch Out for these 4 Indian Companies Betting Big on EV Supply Chain(Views On News)

Jan 11, 2022

The upside in supply chain players could be huge but a delay in the transition to EVs, or any policy related hiccups could end the momentum.

Tech Mahindra's CTC Acquisition: Too Expensive?(Views On News)

Jan 18, 2022

Tech Mahindra's acquisition of European IT-company fails to excite investors.

Time to Buy Energy Stocks(Fast Profits Daily)

Jan 14, 2022

Energy is a sector that looks set to take off. It's time to get in.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Jan 24, 2022 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 5-YR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS